TICKERNERD
Menu
MLTXMLTXHealthcare · Biotechnology

MLTX Stock Forecast: MoonLake Immunotherapeutics Price Predictions for 2026-2027

Last close, 11 Sept 2026
$13
−5.08% on the day

The 15 Wall Street analysts covering MoonLake Immunotherapeutics hold a median 12-month price target of $30 — +139.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
15 / 100
Median analyst target
$30
Analysts covering
15
Revenue$0.0
Operating income−$61.7M
Net income−$61.8M
Free cash flow−$55.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.6%
1M
−24.6%
YTD
−5.1%
1Y
−77.0%
From 52W high
−79.8%
From 52W low
+100.3%
$6
$62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MLTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MoonLake Immunotherapeutics on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
64
Volatility
60
Size
44
Accruals
39
Growth
37
Value
30
Quality
19
Issuance
13
Momentum
3

Revisions (64): Analysts have, on balance, been raising their forecasts.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MLTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MLTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26MLTXHigh $50Median $30Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
11 Buy2 Hold2 Sell
Low $6Median $30High $50

The green dot is the last close — the median target sits +139.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $50
20 July 2026HC Wainwright & Co.ReiteratesBuy$45
20 July 2026HC Wainwright & Co.ReiteratesBuy—
1 July 2026Leerink PartnersMaintainsOutperform$24 → $29
1 July 2026Leerink PartnersMaintainsOutperform—
9 June 2026BTIGReiteratesBuy—
8 June 2026HC Wainwright & Co.ReiteratesBuy—
12 May 2026NeedhamMaintainsBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026BTIGReiteratesBuy—
23 Mar 2026Wolfe ResearchUpgradeOutperform—
19 Mar 2026Rothschild & CoUpgradeBuy—
11 Mar 2026Clear StreetMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Mar 2026RBC CapitalMaintainsSector Perform—
26 Feb 2026NeedhamReiteratesBuy—
24 Feb 2026OppenheimerMaintainsOutperform—
23 Feb 2026BTIGMaintainsBuy—
23 Feb 2026NeedhamMaintainsBuy—
20 Feb 2026RBC CapitalMaintainsSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MLTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, MoonLake Immunotherapeutics returned −77.0% against +17.5% for the S&P 500, dividends included.

MLTX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26MLTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MLTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

MoonLake Immunotherapeutics (MLTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
2.4×

Cheaper than 39% of US stocks

EV / EBITDA
−2.4×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−67.5%

Higher than 18% of US stocks

Return on assets
−32.4%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MoonLake Immunotherapeutics (MLTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MoonLake Immunotherapeutics has a market value of $1.1B and an enterprise value of $629.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$265.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$225.2M.

  • Shares outstanding: 83.6M.

  • Trailing P/E: −3.5×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MoonLake Immunotherapeutics employs 130 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

MLTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MLTXMoonLake Immunotherapeutics$1.1B
15
JANXJanux Therapeutics, Inc.$1.0B
70
ATTOAttovia Therapeutics, Inc.$1.0B
0
SVRASavara, Inc.$1.0B
35
KURAKura Oncology, Inc.$1.0B
79
ABUSArbutus Biopharma Corp.$1.0B
92
CRVSCorvus Pharmaceuticals, Inc.$1.1B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MoonLake Immunotherapeutics — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MLTX news & analysis

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

Seeking Alpha · 8 Sept 2026positive

The article outlines a bull case for MoonLake Immunotherapeutics despite sonelokimab's mixed clinical results, citing regulatory progress and commercial viability. It notes MLTX could file for HS approval without another major trial, potentially accelerating revenue, reducing dilution risk, and with a cash runway projected through mid-2028, while sonelokimab's durability and nanobody structure support its commercial potential.

Why it matters — MLTX watchers would care because the bull case rests on regulatory and commercial pathways—including a potential HS approval without another major trial and reduced dilution risk—rather than requiring clinical superiority.

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

Reuters · 10 Aug 2026positive

MoonLake Immunotherapeutics announced that its experimental drug met all primary goals in a late-stage trial involving adults with an inflammatory disease who had not previously received biologic medicines. The drug was studied in patients with psoriatic arthritis.

Why it matters — A successful late-stage trial for the psoriatic arthritis drug is a significant clinical milestone for MoonLake, potentially supporting its development pipeline.

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 10 Aug 2026positive

MoonLake Immunotherapeutics reported positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve patients with psoriatic arthritis, which met all clinical endpoints at Week 16, including the primary ACR50 endpoint, with no new safety signals identified. The company also reported second quarter 2026 financial results, ending the quarter with $537.0 million in cash and equivalents, expecting a cash runway to mid-2028.

Why it matters — The positive IZAR-1 topline results support sonelokimab's potential entry into the multi-billion dollar psoriatic arthritis market, a key development milestone for MLTX (with full data expected in H1 2027), while the reported cash position outlines the company's financial runway.

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research reports that the consensus price target for MOONLAKE IMMUNO (MLTX) suggests a 73.4% upside, though it notes empirical research shows this metric is hardly effective. The article observes that an upward trend in earnings estimate revisions could indicate near-term upside potential.

Why it matters — MLTX watchers would care because the article highlights the stock's large implied upside based on analyst consensus, while also acknowledging the limited predictive power of price targets.

FAQ

Frequently asked questions about MLTX stock

What is the MLTX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering MoonLake Immunotherapeutics have a median 12-month price target of $30, with estimates ranging from $6 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MLTX stock a buy right now?

Of the 15 analysts covering MoonLake Immunotherapeutics, 11 rate it a Buy, 2 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks MoonLake Immunotherapeutics 15 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MLTX?

As at 12 Sept 2026, MoonLake Immunotherapeutics ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).

Will MLTX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +139.8% from the last close, and Ticker Nerd's factor model ranks MoonLake Immunotherapeutics 15 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MLTX stock forecast for 2030?

No analyst covering MoonLake Immunotherapeutics publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $50 over the next 12 months.

How has MLTX stock performed over the past year?

MoonLake Immunotherapeutics returned -77.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MoonLake Immunotherapeutics do?

MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

What is the latest news on MLTX?

The most recent item we track (Seeking Alpha, 8 Sept 2026): "MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy". The article outlines a bull case for MoonLake Immunotherapeutics despite sonelokimab's mixed clinical results, citing regulatory progress and commercial viability. It notes MLTX could file for HS approval without another major trial, potentially accelerating revenue, reducing dilution risk, and with a cash runway projected through mid-2028, while sonelokimab's durability and nanobody structure support its commercial potential.

Company

About MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. MoonLake’s work centers on advancing targeted immunology treatments for conditions with significant unmet medical needs, positioning the company within the broader biopharmaceutical sector. Its Class A Ordinary Shares provide public-market exposure to a company whose current business is concentrated on clinical development and related biotechnology operations.

CEO Dr. Jorge Santos da Silva Ph.D. · 130 employees · Switzerland · https://www.moonlaketx.com